Atherosclerosis
Volume 196, Issue 2 , Pages 532-541 , February 2008

Lipid management in cardiovascular disease prevention guidelines: Strategies and tactics for implementation

  • Leif R. Erhardt

      Affiliations

    • Department of Cardiology, Malmö University Hospital, Malmö, Sweden
    • Corresponding Author InformationCorresponding author: Professor of Cardiology Department of Cardiology, Malmö University Hospital, SE-205 02 Malmö, Sweden. Tel.: +46 40 240750; fax: +46 40 240751.
    • ,
  • Lawrence A. Leiter

      Affiliations

    • Division of Endocrinology and Metabolism, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • F.D. Richard Hobbs

      Affiliations

    • Department of Primary Care and General Practice, University of Birmingham, Edgbaston, Birmingham, UK

Received 22 February 2007 ,Revised 16 May 2007 ,Accepted 17 May 2007.

References 

  1. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001;285:2486–97.
  2. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice, third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2003;10:S1–S10
  3. Smith SC, Jackson R, Pearson TA, et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Foundation. Circulation. 2004;109:3112–3121
  4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  5. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  6. Erhardt LR, Pearson TA, Bruckert E, et al. Guidelines and their implementation: a discussion document focused on the best approaches to drive improvement. Vasc Dis Prev. 2004;1:167–174
  7. World Health Organization. Global burden of disease estimates 2002. Available at: http://www.who.int/healthinfo/statistics/gbdwhosubregionmortality2002.xls. Accessed October 14, 2004.
  8. EUROASPIRE  A European society of cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE study group. European action on secondary prevention through intervention to reduce events. Eur Heart J. 1997;18:1569–1582
  9. EUROASPIRE II study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II euro heart survey programme. Eur Heart J. 2001;22:554–572
  10. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European society of cardiology, European atherosclerosis society and European society of hypertension. Eur Heart J. 1994;15:1300–1331
  11. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434–503.
  12. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II group. European action on secondary prevention by intervention to reduce events. Lancet 2001;357:995–1001.
  13. Vale MJ, Jelinek MV, Best JD COACH study group. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996–1998 versus 1999–2000. Med J Aust. 2002;176:211–215
  14. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467
  15. Leiter L, Betteridge D.J. The AUDIT study: a worldwide survey of physician attitudes about diabetic dyslipidemia. Poster presented at: American diabetes association 64th annual scientific sessions; June 4–8, 2004. Orlando, FL.
  16. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) survey. Fam Pract. 2002;19:596–604
  17. Erhardt L, Hobbs FD. Public perceptions of cardiovascular risk in five European countries: the REACT survey. Int J Clin Pract. 2002;56:638–644
  18. Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458–1465
  19. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  20. Consoli SM, Bruckert BE. Educational level has a major impact on the representations of cholesterol: a study in 1579 hypercholesterolemic patients. Prev Med. 2004;38:323–329
  21. Department of Health. The National service framework for coronary heart disease. Winning the war on heart disease: progress report 2004. London: Department of health publications; 2004. Available at: www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en. Accessed May 4, 2004.
  22. Yan AT, Tan M, Fitchett D, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian acute coronary syndromes registry). Am J Cardiol. 2004;94:25–29
  23. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
  24. Fitchett DH, Leiter LA, Tardif JC, Goodman SG, Langer A. Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?. Can J Cardiol. 2005;21:85–90
  25. Backlund L. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients?. Prim Health Care Res Dev. 2004;5:145–152
  26. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  27. Emberson JR, Whincup PH, Morris RW, Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J. 2003;24:1719–1726
  28. Nissen S, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA. 2004;292:2217–2226
  29. World Health Organization. Integrated management of cardiovascular risk: report of a WHO meeting, Geneva, 9–12 July 2002. Geneva: World Health Organization; 2002. ISBN 92 4 156224 2.

PII: S0021-9150(07)00367-X

doi: 10.1016/j.atherosclerosis.2007.05.017

Atherosclerosis
Volume 196, Issue 2 , Pages 532-541 , February 2008

Article Tools

* Image Usage & Resolution